BFKB 8488A

Drug Profile

BFKB 8488A

Alternative Names: BFKB8488A; RG 7992; RO 7040551

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech
  • Class Antihyperglycaemics; Bispecific antibodies; Insulin sensitisers
  • Mechanism of Action KLB protein inhibitors; Type 1 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
  • 28 Mar 2017 Genentech completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in USA (NCT02593331)
  • 06 Feb 2017 Genentech initiates enrolment in a phase Ib trial for Type-2 diabetes mellitus in USA (SC) (NCT03060538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top